Latest News for: egfr inhibitor
Edit
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
PR Newswire 15 Jun 2026
... Analysis EGFR Inhibitors Market Size and Trends EGFR Inhibitors Market Opportunity EGFR Inhibitors Market Unmet Needs KOL's Views on EGFR Inhibitors EGFR Inhibitors Market Access and Reimbursement.
Edit
EGFR Inhibitors-induced Skin Disorders Market is Projected to Grow by 2036 Owing to the Rising ...
GetNews 05 Jun 2026
The market dynamics for EGFR Inhibitors-induced Skin Disorders are witnessing significant growth driven by the increasing use of EGFR inhibitors across multiple cancer indications, rising incidence of ...
Edit
Hastings Tribune
18 Mar 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the
Edit
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel ...
Nasdaq Globe Newswire 17 Mar 2026
Edit
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting (Form 8-K) (ArriVent Biopharma Inc)
Public Technologies 17 Mar 2026
Lung cancers with classical EGFR mutations respond to approved EGFR inhibitors, whereas those with EGFR exon 20 insertion (ex20ins) mutations have limited sensitivity and few treatment options.
- 1